PortalPublikationenImproving outcomes in patients with atrial fibrillation: Rat...

Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.

Standard

Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. / Kirchhof, Paulus; Breithardt, Günter; Camm, A John; Crijns, Harry J; Kuck, Karl-Heinz; Vardas, Panos; Wegscheider, Karl.

in: AM HEART J, Jahrgang 166, Nr. 3, 3, 2013, S. 442-448.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kirchhof, P, Breithardt, G, Camm, AJ, Crijns, HJ, Kuck, K-H, Vardas, P & Wegscheider, K 2013, 'Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.', AM HEART J, Jg. 166, Nr. 3, 3, S. 442-448. <http://www.ncbi.nlm.nih.gov/pubmed/24016492?dopt=Citation>

APA

Kirchhof, P., Breithardt, G., Camm, A. J., Crijns, H. J., Kuck, K-H., Vardas, P., & Wegscheider, K. (2013). Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. AM HEART J, 166(3), 442-448. [3]. http://www.ncbi.nlm.nih.gov/pubmed/24016492?dopt=Citation

Vancouver

Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck K-H, Vardas P et al. Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. AM HEART J. 2013;166(3):442-448. 3.

Bibtex

@article{6489d62fe9574d33aaf7b48f7cc6319e,
title = "Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.",
abstract = "Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF). Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF. Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.",
author = "Paulus Kirchhof and G{\"u}nter Breithardt and Camm, {A John} and Crijns, {Harry J} and Karl-Heinz Kuck and Panos Vardas and Karl Wegscheider",
year = "2013",
language = "English",
volume = "166",
pages = "442--448",
journal = "AM HEART J",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.

AU - Kirchhof, Paulus

AU - Breithardt, Günter

AU - Camm, A John

AU - Crijns, Harry J

AU - Kuck, Karl-Heinz

AU - Vardas, Panos

AU - Wegscheider, Karl

PY - 2013

Y1 - 2013

N2 - Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF). Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF. Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.

AB - Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF). Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF. Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.

M3 - SCORING: Journal article

VL - 166

SP - 442

EP - 448

JO - AM HEART J

JF - AM HEART J

SN - 0002-8703

IS - 3

M1 - 3

ER -